Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAndre De Menezes Silva CorraesPKPrashant KapoorCTCarlyn Rose Tan

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals progression-free survival under 2 months for relapsed myeloma patients receiving bispecific antibodies and immunotherapy.

Key Points

  • Median overall survival for patients dual-targeted with bispecific antibodies was only 5.7 months.
  • Results indicated a progression-free survival of 1.77 months after last treatment exposure in relapsed cases.
  • Retrospective multi-center analysis involving 49 relapsed myeloma patients evaluated treatment outcomes.
  • The findings highlight a significant need for improved therapies targeting dual antigen exposure in myeloma.

Cite This Study

Corraes et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9ddhttps://doi.org/10.1182/blood-2025-4598
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network2025
  2. 2Real‐World Treatment Patterns and Clinical Outcomes Among Patients With Triple‐Class–Exposed and BCMA‐Exposed Multiple Myeloma Within the United States2025 · 4 citations
  3. 3Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma with extramedullary disease: Comparative outcomes and evolving strategies2025
  4. 4Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing2025
  5. 5BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025